• 2019.11.26

  Notification of the results of Phase II clinical study of HP-5000 in the U.S. (Transdermal, pain relief and anti-inflammatory patch)(106KB)

• 2019.10.15

  Notification of FDA approval for SECUADO® in the U.S. (Transdermal, schizophrenia treatment patch, development code: HP-3070)(109KB)

• 2019.10.10

  FY02/2020 Q2 Results Earnings Release Presentation

• 2019.09.20

  Notification of approval for manufacturing and marketing approval of HARUROPI® TAPE in Japan (Transdermal, Parkinson's disease treatment patch, development code: HP-3000)(109KB)

• 2019.08.29

  Notification of application for manufacturing and marketing approval of the additional indications of opioid analgesic naive cancer pain relief of FENTOS® TAPE (Transdermal, pain management patch,Development code: HFT-290) in Japan(105KB)